IDEAYA Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for IDEAYA Biosciences (IDYA).

Price Target Range — 13 Quarters

Analyst Consensus — 21 Analysts

2S.Buy

17Buy

2Hold

Consensus RatingBuy# Analysts21Avg. Consensus PT$52Upside to Avg. PT+63.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 16, 2026	William Blair	Alethia Young	Initiate	Outperform	—
Oct 14, 2026	Stifel	Laura Prendergast	Initiate	Buy	$48
Sep 9, 2026	Guggenheim	Paul Jeng	PT Raise	Buy	$54→$57
Sep 1, 2026	Citizens	Silvan Turkcan	Maintained	Market Outperform	$42
Aug 5, 2026	Truist Securities	Gregory Renza	PT Cut	Buy	$63→$59
Aug 5, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$58→$60
Jul 7, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$53→$48
Jul 7, 2026	Truist Securities	Gregory Renza	PT Cut	Buy	$65→$63
Jun 12, 2026	Wedbush	Robert Driscoll	Maintained	Outperform	$58
Jun 2, 2026	Wedbush	Robert Driscoll	Maintained	Outperform	$58
May 7, 2026	Mizuho	Graig Suvannavejh	PT Cut	Outperform	$52→$50
Apr 14, 2026	Goldman Sachs	Corinne Jenkins	PT Raise	Neutral	$31→$35
Apr 14, 2026	Wells Fargo	Eva Fortea Verdejo	PT Raise	Overweight	$44→$48
Apr 14, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$49→$53
Apr 14, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$52→$58
Apr 14, 2026	Guggenheim	Paul Jeng	PT Raise	Buy	$50→$54
Mar 31, 2026	Wedbush	Robert Driscoll	Maintained	Outperform	$52
Feb 19, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$64→$65
Feb 18, 2026	RBC Capital	Leonid Timashev	Maintained	Outperform	$49
Feb 18, 2026	Guggenheim	Paul Jeng	Maintained	Buy	$50

Analyst Ratings News

PRO
William Blair Initiates Coverage On IDEAYA Biosciences with Outperform Rating

William Blair analyst Alethia Young initiates coverage on IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform rating.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on IDEAYA Biosciences, Raises Price Target to $57

Guggenheim analyst Paul Jeng maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and raises the price target from $54 to $57.

Benzinga Newsdesk

PRO
Citizens Reiterates Market Outperform on IDEAYA Biosciences, Maintains $42 Price Target

Citizens analyst Silvan Turkcan reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Market Outperform and maintains $42 price target.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $59

Truist Securities analyst Gregory Renza maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and lowers the price target from $63 to $59.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $60

Wedbush analyst Robert Driscoll maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target from $58 to $60.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $48

RBC Capital analyst Leonid Timashev maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and lowers the price target from $53 to $48.

Benzinga Newsdesk

IDEAYA Biosciences Inc

IDEAYA Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
William Blair Initiates Coverage On IDEAYA Biosciences with Outperform Rating

PRO
Guggenheim Maintains Buy on IDEAYA Biosciences, Raises Price Target to $57

PRO
Citizens Reiterates Market Outperform on IDEAYA Biosciences, Maintains $42 Price Target

PRO
Truist Securities Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $59

PRO
Wedbush Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $60

PRO
RBC Capital Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $48

People Also Watch

People Also Watch

IDEAYA Biosciences Inc

IDEAYA Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROWilliam Blair Initiates Coverage On IDEAYA Biosciences with Outperform Rating

PROGuggenheim Maintains Buy on IDEAYA Biosciences, Raises Price Target to $57

PROCitizens Reiterates Market Outperform on IDEAYA Biosciences, Maintains $42 Price Target

PROTruist Securities Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $59

PROWedbush Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $60

PRORBC Capital Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $48

People Also Watch

People Also Watch

PRO
William Blair Initiates Coverage On IDEAYA Biosciences with Outperform Rating

PRO
Guggenheim Maintains Buy on IDEAYA Biosciences, Raises Price Target to $57

PRO
Citizens Reiterates Market Outperform on IDEAYA Biosciences, Maintains $42 Price Target

PRO
Truist Securities Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $59

PRO
Wedbush Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $60

PRO
RBC Capital Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $48